London, UK; Brentwood, TN, US; 4 January 2007: Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that following completion of the Cash Placing, the Placing and Open Offer, the Glenveigh Licence and the MacroMed Acquisition and as a result of the Directors taking up all of their entitlements under the Placing and Open Offer at a price of 65 pence per share, the following directors’ holdings in Ordinary Shares have changed as set out below:
